PhotoniCare Inc., is a privately held company dedicated to revolutionizing healthcare by equipping healthcare providers with better diagnostic tools, improving clinical outcomes and serving unmet patient & provider needs with the OtoSight™ Middle Ear Scope, utilizing Optical Coherence Tomography (OCT) non-invasive imaging technology. As President & CEO, and as Chairman of the Board of Directors, strategically transforming the market with novel innovation.

Kinova is a global leader in professional robotics. The company's mission was initially to empower individuals with upper-body limitations through the use of assistive robotics. Several years later, the company has evolved its product line to service new markets — helping researchers, medical professionals, governments, businesses and educational institutions achieve their innovation goals through strategic partnerships and collaborative efforts. Today, Kinova provides solutions to professionals in industries such as agrifood, healthcare, security, nuclear, hazmat and advanced manufacturing.

AVITA Medical is a publicly listed (NASDAQ: RCEL, ASX:AVH) regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin.Serving as Chair of the HR/Compensation Committee and as a member of the Audit Committee and Nominating & Corporate Governance Committee.

Innovations was established by Cleveland Clinic leadership to reimagine the way technology is transferred from an academic institution to market. Designed for capabilities far beyond those of a traditional tech transfer office, Innovations’ robust team of market analysts, subject matter experts, and former medical industry leaders have brought actionable insights to every project that has crossed their desks in the last 20 years. Expertise from the external advisory council is solicited to offer strategic advice and identify groups that might benefit from technology licenses, joint development agreements, and more. Innovations brings countless technologies to market, making ideas realities and valid solutions to patient problems … Innovations is proud to move healthcare forward through vital product and business development.

BioProtonics uses Magnetic Resonance Histopathology (MRH) technology as a non-invasive, low cost,MR based alternative to biopsy. For the first time, MRH provides meaningful diagnostic imaging resolution on tissue at the micro-level (sub 1mm). MRH potentially will lead to a safer, less invasive, less costly alternative for many biopsies routinely performed today of which the majority are negative. This advancement will allow for earlier detection of many diseases and cancers and enable more accurate therapies sooner in the disease cycle to improve patient outcomes and lower medical costs.

Bloom Surgical empowers robotic laparoscopic surgeons to resolve intraoperative visual disruptions with an in-abdomen, rapid-response scope lens cleaning tool. LAPAROVISION™ reduces time spent with compromised vision and scope removals, improving patient safety and procedure efficiency. https://www.bloomsurgical.com/

President & CEO July 2022 - May 2023Titan Medical Inc. (Nasdaq: TMDI and TSX: TMD) was focused on robotic-assisted technologies for application in minimally invasive surgery (“MIS”). Enos™ was being developed to become the new standard of care in robotic single access surgery, comprised of a surgeon-controlled patient cart that included a dual-view camera system with 3D and 2D high-definition vision systems and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provided an ergonomic interface to the MIS procedure performed through the patient cart. In 2024, Titan Medical merged with Conavi Medical.Served as Chair of the HR/Compensation Committee and as a member of the Audit Committee and Nominating & Corporate Governance Committee.

Peach IntelliHealth is an AI predictive analytics company. Peach’s AI can predict which patients will have hyperglycemia, hypoglycemia, sepsis, organ failure etc., a full 24-48 hours before onset, so that hospitals can test and treat before patients deteriorate. Peach has the largest array of analytics with superior clinical results, is culturally inclusive, and works across all ICU's, with hospital partners in the US and Asia.

Board Governance, M&A and Investment Consultation, Customer Engagement, Commercial Leadership, Experience Design, Organizational Effectiveness, Strategy and Operations.Helping organizations and individuals improve their performance by solving complex business challenges with effective strategies & systems. Organizational change-management assistance, development of coaching skills, process analysis, technology implementation, strategy development and operational improvement services.

XCath, Inc. is a privately held, endovascular robotics company developing an advanced next-generation endovascular robotic platform, enabling precise manipulation of robotically steerable catheters and guidewires for peripheral vascular and neurovascular clinical applications.As President & CEO, and as a member of the Board of Directors, drove strategic transformation of the emerging endovascular robotic market with the development of a proprietary surgical robotic platform and highly advanced guidewire and catheter technology.

OptiScan Biomedical was a privately-held medical device company, and the developer of aninnovative continuous monitoring system for use in the surgical intensive care unit (SICU). As President and Chief Executive Officer, and as a member of the Board of Directors, led the organization as it leveraged disruptive medical technologies, transformed existing markets, and established new standards that drove OptiScan’s commercialization strategy and activities in the global hospital market.OptiScan Biomedical received FDA clearance for their first-of-its-kind, automated, bedside glucose monitoring system that measures values directly from plasma using spectroscopy technology without the need for calibration. To meet the complex monitoring needs of critically ill patients, OptiScan expanded the OptiScanner platform technology to detect additional metabolic and hemodynamic analytes, providing valuable trending data about the condition of the critically ill patient.As President and Chief Executive Officer, and as a member of the Board of Directors, led an expansive effort towards commercial strategy, operational excellence and clinically relevant innovation.

Myoscience, Inc. (acquired by Pacira Biosciences, Inc) was a privately-held medical device company dedicated to improving patients’ lives by providing innovative, clinically proven, drug-free pain treatments through patented Focused Cold Therapy technology. As President and Chief Executive Officer, and as a member of the Board of Directors, led the company in a turnaround effort towards unprecedented growth and profitability, strategically transforming the business and their markets with disruptive technology.• Built patient, physician and administrative value creation, transforming standard-of-care procedures• Drove adoption and record levels of year-over-year device utilization and revenue levels• Created innovative and focused new product development strategies and commercial initiatives• Strengthened leadership team and interdepartmental collaboration with intensive ROI cultural shift• Executed on financing strategy and a funding round as an integral step to sustainable progression toward profitability• Drove commercial success and executed on a strategic process that led to a $220M acquisition by Pacira BioSciences.

Hansen Medical Inc. (acquired by Auris Health) was a publicly held, rapidly growing global intravascular robotics company that developed and marketed the Sensei®X and Magellan™ Robotic Systems, enabling precise manipulation of robotically steerable catheters for clinical applications in EP and peripheral vascular disease.As President and Chief Executive Officer, and as a member of the Board of Directors, strategically transformed our business and markets with disruptive, enabling and game-changing techniques and technology. Led a turnaround effort that resulted in the sale of the company for double the market capitalization and a 178% premium over the closing stock price the day the company announced it was exploring strategic alternatives to enhance stockholder value. Major shareholders received additional, significant value when Auris Health was acquired by Johnson & Johnson for $5.8B in early 2019.• Built patient, physician and administrative value creation and transforming standard-of-care procedures• Launched new products with an enhanced body of positive clinical data and improved commercial execution• Drove adoption and record levels of year-over-year catheter utilization and system placements• Optimized a globally expansive growth strategy with a broadened and intensified commercial approach• Created innovative and focused new product development strategies and commercial initiatives• Strengthened leadership team and interdepartmental collaboration toward an intensive ROI cultural shift• Significant reduction and reallocation of spend, cash burn, cost of goods, manufacturing variance and inventory levels• Executed on equity and debt financing strategy, as an integral step to the eventual merger and acquisition by Auris Health. Negotiated major Hansen Medical shareholders' Auris Health stock deal• Major Hansen Medical shareholders received additional, significant value when Auris Health was acquired by Johnson & Johnson for $5.8B two years later

Global leader of the $550M Anesthesia and Respiratory business unit for Teleflex. Drove strategic global commercial and product development teams to address the needs of domestic and international markets. Successfully integrated several new organic and acquired product lines to build the strongest portfolio and commercial organization in the marketplace. Established long-term revenue, margin and market share growth beyond market growth rates by building a high performance global organization and an integrated, customer-centric culture.

Led the $700M Teleflex Surgical, Vascular Access, Respiratory, Urology, and Anesthesia businesses in North America to growth beyond market rates. Strengthened and grew product portfolio, services and customer relationships by leveraging strategic sales and marketing teams to address the needs of the North America market. Executive leadership of a management board comprised of sales, marketing, research and development, manufacturing/supply chain, human resources, finance and regulatory affairs/quality assurance. Impacted and accelerated revenue, margin and market share growth by building a high performance organization and customer advocacy across the business.

Led the interventional oncology growth business for the Covidien energy-based device sector in the United States, Canada, and Latin America. Built a high performance international organization and developed our industry reach and expansion. Recognized for record performance with 62% growth and significant penetration in targeted customer segments. Established pricing strategy, training programs, competency modeling, product portfolios, and deployment plans. Built and leveraged a strategic international marketing team to address the needs of the Americas market. Led sales channel development and key drivers to gain market share and support of key opinion leaders.

Led a $400 Million energy-based surgical device business in the US to record performance in FY2008. Responsible for the P&L; led and built teams around the customer and promoted a high level of performance and sustainable growth. Recognized for record performance with 21% growth and significant penetration in targeted procedural areas. Drove marketing and organizational efficiencies to maximize product launches and pricing and cost reduction initiatives. Led sales force expansion and enhanced pricing and compensation models and leadership and competency development.

The GE Healthcare executive in the Northeast; led a $1 Billion diagnostic imaging business of equipment sales and service cross-functional teams, building a customer centric culture across the GE matrix of businesses. Developed two modality marketing leaders and five regional VPs as leaders in our business, while building and implementing growth strategies to win large commercial deals. Drove operational excellence, establishing rigor and process behind metrics, leading the nation in revenue and margin growth.

Led both a $150 Million and $200 Million diagnostic imaging business of equipment sales and service over 4 states. Led and built teams around the customer, sustaining a high level of performance and created a “coaching culture” at all levels. Impacted dysfunctional teams and processes in ways that were immediate and sustainable. Led the region advisory boards to integrate service and sales at all levels. Built and implemented growth strategies – driving large commercial deals. Led the nation in revenue and margin growth over three years.

A rigorous leadership and project management position, working with executives across GE Healthcare to establish and implement strategic vision, driving key growth initiatives throughout headquarters and the sales force.

Drove key strategic account plans throughout the central Texas market and built diagnostic imaging equipment market share and growth metrics that led the nation in revenue over three years.